Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiofarmLTS:0HTH 69 EV-to-EBITDA is 7.95 as of Aug. 13, 2026, which is 43% above its 10-year median of 5.57. GuruFocus rates LTS:0HTH with a GF Score™ of 69/100 and a GF Value™ of lei0.16. The stock has 2 warning signs investors should review. Among 734 Drug Manufacturers companies, Biofarm ranks better than 71.66% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biofarm's enterprise value is lei1,075.2 Mil.
Biofarm's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was lei135.3 Mil. Therefore, Biofarm's EV-to-EBITDA for today is 7.95.
The historical rank and industry rank for Biofarm's EV-to-EBITDA or its related term are showing as below:
LTS:0HTH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.22 Med: 5.57 Max: 9.19
Current: 7.94
During the past 13 years, the highest EV-to-EBITDA of Biofarm was 9.19. The lowest was 3.22. And the median was 5.57.
LTS:0HTH's EV-to-EBITDA is ranked better than 71.66% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.355
vs LTS:0HTH: 7.94
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-13), Biofarm's stock price is lei0.237.
Biofarm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was lei0.103. Therefore, Biofarm's PE Ratio (TTM) for today is 2.30.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biofarm's share price for today is lei0.237.
Biofarm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei0.103.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Biofarm's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HTH vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofarm's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofarm EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofarm's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Biofarm's EV-to-EBITDA falls into.
Biofarm's current Enterprise Value is lei1,075.2 Mil.
Biofarm's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei135.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofarm (LTS:0HTH) has a EV-to-EBITDA of 7.95 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biofarm. This is 43% above median its historical median of 5.57. Over the past decade, Biofarm's EV-to-EBITDA has ranged from 3.22 to 9.19. According to the industry distribution chart, Biofarm ranks #208 out of 734 companies in the Drug Manufacturers industry, placing it in the top 28.3%.
Is Biofarm's EV-to-EBITDA too high?
Biofarm's current EV-to-EBITDA of 7.95 is 43% above median its 10-year median of 5.57. Over the past 10 years, this metric has ranged from a low of 3.22 to a high of 9.19. The Drug Manufacturers industry median EV-to-EBITDA is 13.36. Biofarm's value of 7.95 is 40.5% below this industry median. Based on the distribution chart, Biofarm ranks #208 out of 734 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biofarm has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Biofarm's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofarm ranks #208 out of 734 companies for EV-to-EBITDA. This puts Biofarm in the upper half of its industry. The industry median EV-to-EBITDA is 13.36. Biofarm's value of 7.95 is 40.5% below this benchmark. Historically, Biofarm's own EV-to-EBITDA has ranged from 3.22 to 9.19 over the past decade. While the company's 10-year median is 5.57 vs. the industry median of 13.36, Biofarm has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.36, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofarm's current EV-to-EBITDA of 7.95 is 40.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biofarm. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofarm's current EV-to-EBITDA is 7.95, which is 43% above median its own 10-year median of 5.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Biofarm (LTS:0HTH) has a current EV-to-EBITDA of 7.95. The stock's GF Value™ is lei0.16, compared to a current price of lei0.24 — trading 48.1% above its estimated fair value. The current EV-to-EBITDA is 7.95, which is 43% above median its 10-year median of 5.57 and 40.5% below the Drug Manufacturers industry median of 13.36. Biofarm's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Biofarm (LTS:0HTH), the current EV-to-EBITDA is 7.95 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofarm (LTS:0HTH) Overvalued in 2026?
Based on GuruFocus' analysis, Biofarm stock appears to be overvalued.
The current stock price of lei0.24 is trading 48.1% above its estimated GF Value™ of lei0.16.
Key valuation signals for LTS:0HTH:
EV-to-EBITDA: 7.95 (43% above median its 10-year median of 5.57)
GF Value™: lei0.16 vs. price of lei0.24 (48.1% above fair value)
Industry Position: 40.5% below the Drug Manufacturers median (#208 of 734)
No single metric tells the full story. See the LTS:0HTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
69GF Score
Get the complete analysis for LTS:0HTH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTH has been successfully added to your 
